Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

TEVA – Teva Pharmaceutical Industries Limited

TEVA — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

2.67

Margin Of Safety %

-18

Put/Call OI Ratio

0.5

EPS Next Q Diff

-0.03

EPS Last/This Y

1.11

EPS This/Next Y

0.76

Price

34.07

Target Price

42.11

Analyst Recom

1.43

Performance Q

0.38

Upside

38.8%

Beta

0.85

Ticker: TEVA




22 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-04-23TEVA31.20.480.65452084
2026-04-24TEVA30.640.480.17452779
2026-04-27TEVA31.260.473.31451768
2026-04-28TEVA320.491.86461044
2026-04-29TEVA35.390.540.21487426
2026-04-30TEVA34.960.540.18496382
2026-05-01TEVA34.960.530.29502692
2026-05-04TEVA35.380.530.05493419
2026-05-05TEVA35.880.500.17509299
2026-05-06TEVA36.330.490.43523142
2026-05-07TEVA36.010.500.52527820
2026-05-08TEVA35.740.500.10529655
2026-05-11TEVA35.830.511.08522020
2026-05-12TEVA35.810.510.11523044
2026-05-13TEVA36.230.510.10523402
2026-05-14TEVA35.330.522.20522092
2026-05-15TEVA34.280.490.09517274
2026-05-18TEVA34.040.480.64459376
2026-05-19TEVA34.080.480.48459992
2026-05-20TEVA34.320.481.17461379
2026-05-21TEVA34.140.483.00462801
2026-05-22TEVA34.060.501.44467488
DateSymbolLatestP/C OIP/C VolTotal OI
22 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-04-23TEVA31.20-10.4-63.82.68
2026-04-24TEVA30.64-10.4-101.02.68
2026-04-27TEVA31.26-12.3-89.22.68
2026-04-28TEVA31.65-12.3-90.42.68
2026-04-30TEVA35.08-12.3-73.12.68
2026-05-01TEVA34.97-4.7-229.72.68
2026-05-04TEVA35.36-4.7-206.92.68
2026-05-05TEVA35.87-12.9-217.82.45
2026-05-06TEVA36.33-12.9-220.72.45
2026-05-07TEVA36.01-13.4-211.12.39
2026-05-08TEVA35.74-13.4-281.42.39
2026-05-11TEVA35.83-13.4-254.32.39
2026-05-13TEVA36.24-13.4-191.32.39
2026-05-14TEVA35.31-13.4-263.82.39
2026-05-15TEVA34.26-13.4-280.32.39
2026-05-18TEVA34.05-13.4-258.72.39
2026-05-19TEVA34.10-13.4-245.92.39
2026-05-20TEVA34.28-15.3-219.52.34
2026-05-21TEVA34.13-15.3-238.12.34
2026-05-22TEVA34.07-15.3-254.32.34
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




22 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-04-23TEVA-91.410.712.32
2026-04-24TEVA-95.510.712.32
2026-04-27TEVA-95.510.592.55
2026-04-28TEVA-95.510.592.55
2026-04-29TEVA-95.510.592.55
2026-04-30TEVA-95.510.592.55
2026-05-01TEVA-95.510.592.55
2026-05-04TEVA-91.900.792.55
2026-05-05TEVA-91.900.792.55
2026-05-06TEVA-91.900.792.55
2026-05-07TEVA-92.010.792.55
2026-05-08TEVA-95.840.792.55
2026-05-11TEVA-95.500.572.55
2026-05-12TEVA-95.500.572.67
2026-05-13TEVA-95.500.572.67
2026-05-14TEVA-95.500.572.67
2026-05-15TEVA-95.500.572.67
2026-05-18TEVA-95.772.012.67
2026-05-19TEVA-91.882.012.67
2026-05-20TEVA-95.772.012.67
2026-05-21TEVA-95.772.012.67
2026-05-22TEVA-95.772.012.67
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
22 items Current Page1 of 1

Last Quarter Act. EPS

0.5

Avg. EPS Est. Current Quarter

0.56

Avg. EPS Est. Next Quarter

0.47

Insider Transactions

-95.77

Institutional Transactions

2.01

Beta

0.85

Average Sales Estimate Current Quarter

4065

Average Sales Estimate Next Quarter

4244

Fair Value

28.06

Quality Score

74

Growth Score

41

Sentiment Score

33

Actual DrawDown %

8.8

Max Drawdown 5-Year %

-43.7

Target Price

42.11

P/E

25.3

Forward P/E

10.98

PEG

2.02

P/S

2.26

P/B

4.82

P/Free Cash Flow

89.25

EPS

1.35

Average EPS Est. Cur. Y​

2.34

EPS Next Y. (Est.)

3.1

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

8.98

Relative Volume

0.4

Return on Equity vs Sector %

-8

Return on Equity vs Industry %

10.9

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.34

EBIT Estimation

-254.3
TEVA Healthcare
$34.04
📉
Swing / Pullback
Buy the dip on strong trends
47 /100
WEAK
Trend
2/20
Pullback
13/25
Volume
11/15
Valuation
11/20
TP/AR
4/10
Options
6/10
RSI
51.2
Range 1M
57.9%
Sup Dist
0.6%
🚀
Momentum Growth
Ride accelerating trends
N/A
37 /100
WEAK
Momentum
5/25
Growth
17/30
Estimates
5/20
Inst/Vol
6/15
Options
4/10
EPS Yr
-23%
EPS NY
37.5%
52W%
85.3%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +108.8% upside
Quality
12/30
Valuation
17/30
Growth
12/25
Stability
2/10
LT Trend
1/5
Upside
+108.8%
Quality
74
MoS
-18%
Teva Pharmaceutical Industries
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 31173
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO to treat neurodegenerative and movement disorders – chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv-Yafo, Israel.
TEVA

Latest News

Caricamento notizie per TEVA
stock quote shares TEVA – Teva Pharmaceutical Industries Limited Stock Price stock today
news today TEVA – Teva Pharmaceutical Industries Limited stock forecast ,stock prediction 2023 2024 2025
marketwatch TEVA – Teva Pharmaceutical Industries Limited yahoo finance google finance
stock history TEVA – Teva Pharmaceutical Industries Limited invest stock market
stock prices TEVA premarket after hours
ticker TEVA fair value insiders trading